View Financial HealthDecipher Labs 배당 및 자사주 매입배당 기준 점검 0/6Decipher Labs 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.53 loss per share (vs ₹0.59 loss in 3Q 2025)Third quarter 2026 results: ₹0.53 loss per share (improved from ₹0.59 loss in 3Q 2025). Revenue: ₹32.3m (down 46% from 3Q 2025). Net loss: ₹5.39m (loss narrowed 9.1% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 26% per year.공시 • Feb 09Decipher Labs Limited to Report Q3, 2026 Results on Feb 12, 2026Decipher Labs Limited announced that they will report Q3, 2026 results on Feb 12, 2026New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹65m free cash flow). Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹105.5m market cap, or US$1.17m). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Revenue is less than US$5m (₹176m revenue, or US$2.0m).Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹0.02 (vs ₹1.31 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.02 (up from ₹1.31 loss in 2Q 2025). Revenue: ₹43.3m (down 28% from 2Q 2025). Net income: ₹201.0k (up ₹13.5m from 2Q 2025). Profit margin: 0.5% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.공시 • Nov 11Decipher Labs Limited to Report Q2, 2026 Results on Nov 13, 2025Decipher Labs Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025공시 • Sep 08Decipher Labs Limited, Annual General Meeting, Sep 30, 2025Decipher Labs Limited, Annual General Meeting, Sep 30, 2025, at 11:00 Indian Standard Time.Reported Earnings • Aug 16First quarter 2026 earnings released: ₹3.39 loss per share (vs ₹0.94 profit in 1Q 2025)First quarter 2026 results: ₹3.39 loss per share (down from ₹0.94 profit in 1Q 2025). Revenue: ₹29.3m (down 61% from 1Q 2025). Net loss: ₹34.3m (down 462% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.공시 • Aug 12Decipher Labs Limited to Report Q1, 2026 Results on Aug 14, 2025Decipher Labs Limited announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • Jun 02Full year 2025 earnings released: ₹5.03 loss per share (vs ₹1.66 loss in FY 2024)Full year 2025 results: ₹5.03 loss per share (further deteriorated from ₹1.66 loss in FY 2024). Revenue: ₹239.3m (down 34% from FY 2024). Net loss: ₹50.8m (loss widened 203% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 15Third quarter 2025 earnings released: ₹0.59 loss per share (vs ₹0.01 profit in 3Q 2024)Third quarter 2025 results: ₹0.59 loss per share (down from ₹0.01 profit in 3Q 2024). Revenue: ₹59.7m (down 28% from 3Q 2024). Net loss: ₹5.93m (down ₹6.03m from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.공시 • Jan 02Decipher Labs Limited Appoints Preeti Singh as Company Secretary and Compliance Officer, with Effect from January 01, 2025The board of directors of Decipher Labs Limited at its meeting held on 31 December, 2024, Appointment of Ms. Preeti Singh as the Company Secretary and Compliance Officer of the Company with effect from January 01, 2025. Ms. Preeti Singh is a qualified Company Secretary and legal professional. She is having rich experience in Secretarial and legal works for 3 years.Reported Earnings • Nov 16Second quarter 2025 earnings released: ₹1.31 loss per share (vs ₹1.92 loss in 2Q 2024)Second quarter 2025 results: ₹1.31 loss per share (improved from ₹1.92 loss in 2Q 2024). Revenue: ₹59.9m (down 20% from 2Q 2024). Net loss: ₹13.3m (loss narrowed 32% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.공시 • Sep 26Decipher Labs Limited Announces Executive ChangesDecipher Labs Limited announced that the Mr. Siva Kumar Reddy Chappidi has resigned from the post of Company Secretary and Compliance Officer with effect from 30 September 2024 (post-closing hour) due to personal reasons. Mr. Sushant Mohan Lal, Executive Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.공시 • Sep 04+ 2 more updatesDecipher Labs Limited to Report Q2, 2025 Results on Nov 14, 2024Decipher Labs Limited announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 20First quarter 2025 earnings released: EPS: ₹0.94 (vs ₹0.94 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.94 (up from ₹0.94 loss in 1Q 2024). Revenue: ₹74.4m (down 22% from 1Q 2024). Net income: ₹9.47m (up ₹18.9m from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.공시 • Aug 16Decipher Labs Limited, Annual General Meeting, Sep 30, 2024Decipher Labs Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time.공시 • Aug 09Decipher Labs Limited to Report Q1, 2025 Results on Aug 14, 2024Decipher Labs Limited announced that they will report Q1, 2025 results on Aug 14, 2024New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.8% per year over the past 5 years. Market cap is less than US$10m (₹180.2m market cap, or US$2.16m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹351m revenue, or US$4.2m).New Risk • Feb 16New major risk - Revenue and earnings growthEarnings have declined by 6.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.7% per year over the past 5 years. Market cap is less than US$10m (₹187.3m market cap, or US$2.26m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹280m revenue, or US$3.4m).Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Whole-Time Director Sushant Lal is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Sep 17Decipher Labs Limited Announces Executive ChangesMudunuru Limited announced that Mr. Pankaj Tulsayani has resigned from the post of Company Secretary and Compliance Officer of Decipher Labs Limited with effect from September 16, 2023 (After close of business hours). Mr. Madhusudan Raju Mudunuru, Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.공시 • Sep 07+ 2 more updatesDecipher Labs Limited to Report Q4, 2024 Results on May 30, 2024Decipher Labs Limited announced that they will report Q4, 2024 results on May 30, 2024공시 • Sep 05+ 1 more updateDecipher Labs Limited, Annual General Meeting, Sep 30, 2023Decipher Labs Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time.New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₹356m (US$4.3m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹159.4m market cap, or US$1.92m). Minor Risk Revenue is less than US$5m (₹356m revenue, or US$4.3m).Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.94 loss per share (vs ₹5.85 profit in 1Q 2023)First quarter 2024 results: ₹0.94 loss per share (down from ₹5.85 profit in 1Q 2023). Revenue: ₹95.1m (down 25% from 1Q 2023). Net loss: ₹9.48m (down 116% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.공시 • Aug 08Decipher Labs Limited to Report Q1, 2024 Results on Aug 14, 2023Decipher Labs Limited announced that they will report Q1, 2024 results on Aug 14, 2023공시 • Jul 22Decipher Labs Limited Announces Company Secretary and Compliance Officer ChangesDecipher Labs Limited at its board meeting held on July 19, 2023, resignation of Ms. Megha Agarwal as Company Secretary and Compliance Officer of the Company effective June 30, 2023, appointment of Mr. Siva Kumar Reddy Chappidi as Company Secretary and Compliance Officer of the Company effective July 19, 2023. Mr. C. Siva Kumar Reddy is a qualified Company Secretary and is having working knowledge in Secretarial matters.Reported Earnings • Jun 01Full year 2023 earnings released: ₹2.66 loss per share (vs ₹11.27 profit in FY 2022)Full year 2023 results: ₹2.66 loss per share (down from ₹11.27 profit in FY 2022). Revenue: ₹529.4m (down 19% from FY 2022). Net loss: ₹26.8m (down 124% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Feb 08Decipher Labs Limited to Report Q3, 2023 Results on Feb 14, 2023Decipher Labs Limited announced that they will report Q3, 2023 results on Feb 14, 2023Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹33.80, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹35.00, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 79% over the past three years.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹52.60, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years.공시 • Aug 30Decipher Labs Limited, Annual General Meeting, Sep 29, 2022Decipher Labs Limited, Annual General Meeting, Sep 29, 2022, at 11:30 Indian Standard Time.Reported Earnings • Aug 18First quarter 2023 earnings released: EPS: ₹5.85 (vs ₹0.66 in 1Q 2022)First quarter 2023 results: EPS: ₹5.85 (up from ₹0.66 in 1Q 2022). Revenue: ₹194.8m (up 45% from 1Q 2022). Net income: ₹59.1m (up ₹52.4m from 1Q 2022). Profit margin: 30% (up from 5.0% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 124% over the past three years.공시 • Jul 30Decipher Labs Limited to Report Q1, 2023 Results on Aug 13, 2022Decipher Labs Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Aug 13, 2022Reported Earnings • May 18Full year 2022 earnings released: EPS: ₹11.27 (vs ₹1.39 in FY 2021)Full year 2022 results: EPS: ₹11.27 (up from ₹1.39 in FY 2021). Revenue: ₹730.0m (up 31% from FY 2021). Net income: ₹113.8m (up ₹99.8m from FY 2021). Profit margin: 16% (up from 2.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹43.30, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹61.75, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 138% over the past three years.Recent Insider Transactions • Mar 21CEO & Whole Time Director recently sold ₹421k worth of stockOn the 16th of March, Janakiram Ajjarapu sold around 6k shares on-market at roughly ₹67.30 per share. This was the largest sale by an insider in the last 3 months. This was Janakiram's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹62.00, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 173% over the past three years.Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹7.21 (up from ₹0.10 in 3Q 2021). Revenue: ₹210.2m (up 53% from 3Q 2021). Net income: ₹72.8m (up ₹71.8m from 3Q 2021). Profit margin: 35% (up from 0.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₹61.05, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 194% over the past three years.공시 • Feb 04Decipher Labs Limited to Report Q3, 2022 Results on Feb 14, 2022Decipher Labs Limited announced that they will report Q3, 2022 results on Feb 14, 2022Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹81.90, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 301% over the past three years.Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 57% share price gain to ₹59.95, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 153% over the past three years.Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹36.60, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years.Reported Earnings • Jul 02Full year 2021 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹562.1m (up 134% from FY 2020). Net income: ₹14.0m (up 27% from FY 2020). Profit margin: 2.5% (down from 4.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹42.10, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years.Valuation Update With 7 Day Price Move • May 16Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.35, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years.Valuation Update With 7 Day Price Move • Apr 30Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹31.80, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years.Reported Earnings • Feb 15Third quarter 2021 earnings released: EPS ₹0.10The company reported a decent third quarter result with improved revenues, although earnings and profit margins were weaker. Third quarter 2021 results: Revenue: ₹137.8m (up 270% from 3Q 2020). Net income: ₹1.04m (down 60% from 3Q 2020). Profit margin: 0.8% (down from 7.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.공시 • Feb 07Decipher Labs Limited to Report Q3, 2021 Results on Feb 13, 2021Decipher Labs Limited announced that they will report Q3, 2021 results on Feb 13, 2021Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹35.20, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 21.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 76%.Is New 90 Day High Low • Dec 14New 90-day high: ₹29.10The company is up 29% from its price of ₹22.50 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 15% share price gain to ₹28.85, the stock is trading at a trailing P/E ratio of 21.8x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 44%.Is New 90 Day High Low • Nov 23New 90-day high: ₹26.05The company is up 3.0% from its price of ₹25.25 on 25 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 15% share price gain to ₹24.85, the stock is trading at a trailing P/E ratio of 18.8x, up from the previous P/E ratio of 16.3x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%.Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS ₹0.31The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ₹136.1m (up ₹123.8m from 2Q 2020). Net income: ₹3.09m (up ₹2.58m from 2Q 2020). Profit margin: 2.3% (down from 4.2% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공시 • Nov 05Decipher Labs Limited to Report Q2, 2021 Results on Nov 12, 2020Decipher Labs Limited announced that they will report Q2, 2021 results on Nov 12, 2020공시 • Oct 02Decipher Labs Limited Approves Board ChangesDecipher Labs Limited at its board meeting held on October 1, 2020 approved the appointment of the Promoter of the company Mr. Janakiram Ajjarapu as an Additional Director (Executive Director) and Key Managerial Person of the Company with effect from October 01, 2020. Further, in compliance with the circulars issued by BSE Limited, the company confirmed that Mr. Janakiram Ajjarapu has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority. Also, he is not related to any Director or Key Managerial Personnel. The company further announced that Mr. Vasudev Kommaraju, Director of the company did not seek re-appointment in the Annual General meeting held on 29th September, 2020 and has ceased to be a Director of the company.Is New 90 Day High Low • Sep 24New 90-day low: ₹19.20The company is down 27% from its price of ₹26.25 on 26 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.공시 • Aug 25Decipher Labs Limited to Report Q1, 2021 Results on Sep 01, 2020Decipher Labs Limited announced that they will report Q1, 2021 results on Sep 01, 2020공시 • Jun 20Decipher Labs Limited to Report Q4, 2020 Results on Jun 29, 2020Decipher Labs Limited announced that they will report Q4, 2020 results on Jun 29, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 524752 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 524752 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Decipher Labs 배당 수익률 vs 시장524752의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (524752)n/a시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Pharmaceuticals)0.7%분석가 예측 (524752) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 524752 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 524752 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 524752 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 524752 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 20:37종가2026/05/22 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Decipher Labs Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.53 loss per share (vs ₹0.59 loss in 3Q 2025)Third quarter 2026 results: ₹0.53 loss per share (improved from ₹0.59 loss in 3Q 2025). Revenue: ₹32.3m (down 46% from 3Q 2025). Net loss: ₹5.39m (loss narrowed 9.1% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 26% per year.
공시 • Feb 09Decipher Labs Limited to Report Q3, 2026 Results on Feb 12, 2026Decipher Labs Limited announced that they will report Q3, 2026 results on Feb 12, 2026
New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹65m free cash flow). Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹105.5m market cap, or US$1.17m). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Revenue is less than US$5m (₹176m revenue, or US$2.0m).
Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: ₹0.02 (vs ₹1.31 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.02 (up from ₹1.31 loss in 2Q 2025). Revenue: ₹43.3m (down 28% from 2Q 2025). Net income: ₹201.0k (up ₹13.5m from 2Q 2025). Profit margin: 0.5% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
공시 • Nov 11Decipher Labs Limited to Report Q2, 2026 Results on Nov 13, 2025Decipher Labs Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025
공시 • Sep 08Decipher Labs Limited, Annual General Meeting, Sep 30, 2025Decipher Labs Limited, Annual General Meeting, Sep 30, 2025, at 11:00 Indian Standard Time.
Reported Earnings • Aug 16First quarter 2026 earnings released: ₹3.39 loss per share (vs ₹0.94 profit in 1Q 2025)First quarter 2026 results: ₹3.39 loss per share (down from ₹0.94 profit in 1Q 2025). Revenue: ₹29.3m (down 61% from 1Q 2025). Net loss: ₹34.3m (down 462% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.
공시 • Aug 12Decipher Labs Limited to Report Q1, 2026 Results on Aug 14, 2025Decipher Labs Limited announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • Jun 02Full year 2025 earnings released: ₹5.03 loss per share (vs ₹1.66 loss in FY 2024)Full year 2025 results: ₹5.03 loss per share (further deteriorated from ₹1.66 loss in FY 2024). Revenue: ₹239.3m (down 34% from FY 2024). Net loss: ₹50.8m (loss widened 203% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 15Third quarter 2025 earnings released: ₹0.59 loss per share (vs ₹0.01 profit in 3Q 2024)Third quarter 2025 results: ₹0.59 loss per share (down from ₹0.01 profit in 3Q 2024). Revenue: ₹59.7m (down 28% from 3Q 2024). Net loss: ₹5.93m (down ₹6.03m from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
공시 • Jan 02Decipher Labs Limited Appoints Preeti Singh as Company Secretary and Compliance Officer, with Effect from January 01, 2025The board of directors of Decipher Labs Limited at its meeting held on 31 December, 2024, Appointment of Ms. Preeti Singh as the Company Secretary and Compliance Officer of the Company with effect from January 01, 2025. Ms. Preeti Singh is a qualified Company Secretary and legal professional. She is having rich experience in Secretarial and legal works for 3 years.
Reported Earnings • Nov 16Second quarter 2025 earnings released: ₹1.31 loss per share (vs ₹1.92 loss in 2Q 2024)Second quarter 2025 results: ₹1.31 loss per share (improved from ₹1.92 loss in 2Q 2024). Revenue: ₹59.9m (down 20% from 2Q 2024). Net loss: ₹13.3m (loss narrowed 32% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.
공시 • Sep 26Decipher Labs Limited Announces Executive ChangesDecipher Labs Limited announced that the Mr. Siva Kumar Reddy Chappidi has resigned from the post of Company Secretary and Compliance Officer with effect from 30 September 2024 (post-closing hour) due to personal reasons. Mr. Sushant Mohan Lal, Executive Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.
공시 • Sep 04+ 2 more updatesDecipher Labs Limited to Report Q2, 2025 Results on Nov 14, 2024Decipher Labs Limited announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 20First quarter 2025 earnings released: EPS: ₹0.94 (vs ₹0.94 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.94 (up from ₹0.94 loss in 1Q 2024). Revenue: ₹74.4m (down 22% from 1Q 2024). Net income: ₹9.47m (up ₹18.9m from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.
공시 • Aug 16Decipher Labs Limited, Annual General Meeting, Sep 30, 2024Decipher Labs Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time.
공시 • Aug 09Decipher Labs Limited to Report Q1, 2025 Results on Aug 14, 2024Decipher Labs Limited announced that they will report Q1, 2025 results on Aug 14, 2024
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.8% per year over the past 5 years. Market cap is less than US$10m (₹180.2m market cap, or US$2.16m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹351m revenue, or US$4.2m).
New Risk • Feb 16New major risk - Revenue and earnings growthEarnings have declined by 6.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.7% per year over the past 5 years. Market cap is less than US$10m (₹187.3m market cap, or US$2.26m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹280m revenue, or US$3.4m).
Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Whole-Time Director Sushant Lal is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Sep 17Decipher Labs Limited Announces Executive ChangesMudunuru Limited announced that Mr. Pankaj Tulsayani has resigned from the post of Company Secretary and Compliance Officer of Decipher Labs Limited with effect from September 16, 2023 (After close of business hours). Mr. Madhusudan Raju Mudunuru, Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer.
공시 • Sep 07+ 2 more updatesDecipher Labs Limited to Report Q4, 2024 Results on May 30, 2024Decipher Labs Limited announced that they will report Q4, 2024 results on May 30, 2024
공시 • Sep 05+ 1 more updateDecipher Labs Limited, Annual General Meeting, Sep 30, 2023Decipher Labs Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time.
New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₹356m (US$4.3m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹159.4m market cap, or US$1.92m). Minor Risk Revenue is less than US$5m (₹356m revenue, or US$4.3m).
Reported Earnings • Aug 16First quarter 2024 earnings released: ₹0.94 loss per share (vs ₹5.85 profit in 1Q 2023)First quarter 2024 results: ₹0.94 loss per share (down from ₹5.85 profit in 1Q 2023). Revenue: ₹95.1m (down 25% from 1Q 2023). Net loss: ₹9.48m (down 116% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
공시 • Aug 08Decipher Labs Limited to Report Q1, 2024 Results on Aug 14, 2023Decipher Labs Limited announced that they will report Q1, 2024 results on Aug 14, 2023
공시 • Jul 22Decipher Labs Limited Announces Company Secretary and Compliance Officer ChangesDecipher Labs Limited at its board meeting held on July 19, 2023, resignation of Ms. Megha Agarwal as Company Secretary and Compliance Officer of the Company effective June 30, 2023, appointment of Mr. Siva Kumar Reddy Chappidi as Company Secretary and Compliance Officer of the Company effective July 19, 2023. Mr. C. Siva Kumar Reddy is a qualified Company Secretary and is having working knowledge in Secretarial matters.
Reported Earnings • Jun 01Full year 2023 earnings released: ₹2.66 loss per share (vs ₹11.27 profit in FY 2022)Full year 2023 results: ₹2.66 loss per share (down from ₹11.27 profit in FY 2022). Revenue: ₹529.4m (down 19% from FY 2022). Net loss: ₹26.8m (down 124% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Feb 08Decipher Labs Limited to Report Q3, 2023 Results on Feb 14, 2023Decipher Labs Limited announced that they will report Q3, 2023 results on Feb 14, 2023
Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹33.80, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹35.00, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 79% over the past three years.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹52.60, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years.
공시 • Aug 30Decipher Labs Limited, Annual General Meeting, Sep 29, 2022Decipher Labs Limited, Annual General Meeting, Sep 29, 2022, at 11:30 Indian Standard Time.
Reported Earnings • Aug 18First quarter 2023 earnings released: EPS: ₹5.85 (vs ₹0.66 in 1Q 2022)First quarter 2023 results: EPS: ₹5.85 (up from ₹0.66 in 1Q 2022). Revenue: ₹194.8m (up 45% from 1Q 2022). Net income: ₹59.1m (up ₹52.4m from 1Q 2022). Profit margin: 30% (up from 5.0% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 124% over the past three years.
공시 • Jul 30Decipher Labs Limited to Report Q1, 2023 Results on Aug 13, 2022Decipher Labs Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Aug 13, 2022
Reported Earnings • May 18Full year 2022 earnings released: EPS: ₹11.27 (vs ₹1.39 in FY 2021)Full year 2022 results: EPS: ₹11.27 (up from ₹1.39 in FY 2021). Revenue: ₹730.0m (up 31% from FY 2021). Net income: ₹113.8m (up ₹99.8m from FY 2021). Profit margin: 16% (up from 2.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹43.30, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹61.75, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 138% over the past three years.
Recent Insider Transactions • Mar 21CEO & Whole Time Director recently sold ₹421k worth of stockOn the 16th of March, Janakiram Ajjarapu sold around 6k shares on-market at roughly ₹67.30 per share. This was the largest sale by an insider in the last 3 months. This was Janakiram's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹62.00, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 173% over the past three years.
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹7.21 (up from ₹0.10 in 3Q 2021). Revenue: ₹210.2m (up 53% from 3Q 2021). Net income: ₹72.8m (up ₹71.8m from 3Q 2021). Profit margin: 35% (up from 0.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₹61.05, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 194% over the past three years.
공시 • Feb 04Decipher Labs Limited to Report Q3, 2022 Results on Feb 14, 2022Decipher Labs Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹81.90, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 301% over the past three years.
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 57% share price gain to ₹59.95, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 153% over the past three years.
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹36.60, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years.
Reported Earnings • Jul 02Full year 2021 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹562.1m (up 134% from FY 2020). Net income: ₹14.0m (up 27% from FY 2020). Profit margin: 2.5% (down from 4.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹42.10, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years.
Valuation Update With 7 Day Price Move • May 16Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.35, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years.
Valuation Update With 7 Day Price Move • Apr 30Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹31.80, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years.
Reported Earnings • Feb 15Third quarter 2021 earnings released: EPS ₹0.10The company reported a decent third quarter result with improved revenues, although earnings and profit margins were weaker. Third quarter 2021 results: Revenue: ₹137.8m (up 270% from 3Q 2020). Net income: ₹1.04m (down 60% from 3Q 2020). Profit margin: 0.8% (down from 7.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
공시 • Feb 07Decipher Labs Limited to Report Q3, 2021 Results on Feb 13, 2021Decipher Labs Limited announced that they will report Q3, 2021 results on Feb 13, 2021
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹35.20, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 21.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 76%.
Is New 90 Day High Low • Dec 14New 90-day high: ₹29.10The company is up 29% from its price of ₹22.50 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 15% share price gain to ₹28.85, the stock is trading at a trailing P/E ratio of 21.8x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 44%.
Is New 90 Day High Low • Nov 23New 90-day high: ₹26.05The company is up 3.0% from its price of ₹25.25 on 25 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 15% share price gain to ₹24.85, the stock is trading at a trailing P/E ratio of 18.8x, up from the previous P/E ratio of 16.3x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%.
Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS ₹0.31The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ₹136.1m (up ₹123.8m from 2Q 2020). Net income: ₹3.09m (up ₹2.58m from 2Q 2020). Profit margin: 2.3% (down from 4.2% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공시 • Nov 05Decipher Labs Limited to Report Q2, 2021 Results on Nov 12, 2020Decipher Labs Limited announced that they will report Q2, 2021 results on Nov 12, 2020
공시 • Oct 02Decipher Labs Limited Approves Board ChangesDecipher Labs Limited at its board meeting held on October 1, 2020 approved the appointment of the Promoter of the company Mr. Janakiram Ajjarapu as an Additional Director (Executive Director) and Key Managerial Person of the Company with effect from October 01, 2020. Further, in compliance with the circulars issued by BSE Limited, the company confirmed that Mr. Janakiram Ajjarapu has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority. Also, he is not related to any Director or Key Managerial Personnel. The company further announced that Mr. Vasudev Kommaraju, Director of the company did not seek re-appointment in the Annual General meeting held on 29th September, 2020 and has ceased to be a Director of the company.
Is New 90 Day High Low • Sep 24New 90-day low: ₹19.20The company is down 27% from its price of ₹26.25 on 26 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
공시 • Aug 25Decipher Labs Limited to Report Q1, 2021 Results on Sep 01, 2020Decipher Labs Limited announced that they will report Q1, 2021 results on Sep 01, 2020
공시 • Jun 20Decipher Labs Limited to Report Q4, 2020 Results on Jun 29, 2020Decipher Labs Limited announced that they will report Q4, 2020 results on Jun 29, 2020